The University of Freiburg, officially the Albert Ludwig University of Freiburg, is a public research university located in Freiburg im Breisgau, Baden-Württemberg, Germany.

During the past decade, University of Freiburg conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 7 clinical trials were completed, i.e. on average, 63.6% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Freiburg" #1 sponsor was "Shire" with 4 trials, followed by "Human Genome Sciences Inc." with 3 trials sponsored, "Gilead Sciences" with 2 trials sponsored, "University of Cologne" with 2 trials sponsored and "University of Ulm" with 2 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Freiburg" #1 collaborator was "Novartis" with 3 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator, "ABX CRO" with 1 trials as a collaborator, "Agios Pharmaceuticals, Inc." with 1 trials as a collaborator and "Bolton Medical" with 1 trials as a collaborator. Other collaborators include 10 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "University of Freiburg" are "Hepatitis C, Chronic" (3 trials), "Aortic Dissection" (2 trials), "Chronic Hepatitis C" (2 trials), "Epilepsy" (2 trials) and "Stroke" (2 trials). Many other conditions were trialed in "University of Freiburg" in a lesser frequency.

Most popular intervention types in "University of Freiburg" are "Drug" (19 trials), "Other" (5 trials), "Behavioral" (3 trials), "Device" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ribavirin" (3 trials), "albumin interferon alfa-2b" (2 trials), "peginterferon alfa-2a" (2 trials), "placebo" (2 trials) and "ACE inhibitor, angiotensin receptor blocker" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Freiburg" are 33 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University of Freiburg". 1 are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in University of Freiburg, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in University of Freiburg, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 4 trials that are defined as “Not Applicable".

University of Freiburg has several departments that took part in Clinical trials: "Prof. Anca-Ligia Grosu" - 2 trials